Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00312130 · ClinicalTrials.gov registry record · Phase 3
A Study to Evaluate the Effects of Vildagliptin on the Insulin Response to Glucose in Subjects With Pre-diabetes
A Phase 3 study of Pre Diabetes, sponsored by Novartis.
- Completed
- Registry status
- Phase 3
- Development phase
- 20
- Enrollment target
- 1
- Study location
NCT00312130 is a Phase 3 study of Pre Diabetes that has completed, run by Novartis. The registered enrollment target is 20 participants, below the 729-participant average among 59 other Pre Diabetes trials with a reported enrollment target (97% lower). The trial reports 1 study location across 1 state.
The verdict
NCT00312130, a Phase 3 study of Pre Diabetes, has completed, sponsored by Novartis.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 20 participants
- Enrollment target
- 1
- Study location
Study Summary
This is an exploratory study to assess whether vildagliptin, an unapproved drug, can increase insulin secretion in subjects with pre-diabetes who have a defect in the insulin response and elevated levels of fasting glucose.
Conditions Studied
Interventions
- DRUG Vildagliptin
Study Locations (1)
Washington
- University of Washington - Seattle
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 20 participants |
| Start Date | 2005-04 |
| Est. Completion | 2006-11 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00312130
The ClinicalTrials.gov registry entry for NCT00312130 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 20 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 729-participant average among 59 other Pre Diabetes trials with a reported enrollment target (97% lower). The listed sponsor is Novartis, which has 265 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Pre Diabetes appearing as the primary indexed condition, and to 1 intervention - of which Vildagliptin is the first listed.
NCT00312130 reports 1 study location spanning 1 distinct geographic area - top geographies include Washington.
Frequently Asked Questions
What is clinical trial NCT00312130 about?
NCT00312130 is a clinical study titled "A Study to Evaluate the Effects of Vildagliptin on the Insulin Response to Glucose in Subjects With Pre-diabetes". This is an exploratory study to assess whether vildagliptin, an unapproved drug, can increase insulin secretion in subjects with pre-diabetes who have a defect in the insulin response and elevated levels of fasting glucose.
What is the current status of trial NCT00312130?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 20 participants. The study started on 2005-04. Estimated completion is 2006-11.
What conditions does trial NCT00312130 study?
This clinical trial studies the following conditions: Pre Diabetes.
What interventions are being tested in trial NCT00312130?
The interventions under investigation include: Vildagliptin (DRUG).
Who is sponsoring clinical trial NCT00312130?
This trial is sponsored by Novartis, which has 265 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00312130 being conducted?
This trial has 1 study location across Washington. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Pre Diabetes
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Efficacy of Viome's Precision Nutrition Program Towards Reducing HbA1c
RECRUITING · NA
-
Treatment to Regress to Normoglycemia in Women with a Recent History of GDM
RECRUITING · Phase 4
-
Optimizing Mango's Glycemic Impact: Investigating Mango Consumption Timing in Prediabetic Individuals
RECRUITING · NA
-
Glycemic Metrics and Patterns in People With and Without Prediabetes
RECRUITING
-
MegaNatural BP® GSE on Blood Pressure and Cardiometabolic Risk Factors
RECRUITING · NA
-
Stand Up for Your Health with a Sit-stand Desk
RECRUITING · NA
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.